Evidence map›Paper›PMID 33398258›Full record

ReviewMedicine in drug discovery2021

Emerging peptide antibiotics with therapeutic potential.

Gregory Upert, Anatol Luther, Daniel Obrecht, Philipp Ermert

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Medicine in drug discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 1 synthesis or guideline pooled it, 78 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. A Chronicle Review ofIndian journal of microbiology · 2024
    Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Using display technologies to identify macrocyclic peptide antibiotics.Biochimica et biophysica acta. Molecular cell research · 2023
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Gregory UpertPolyphor Ltd, Hegenheimermattweg 125, 4123 Allschwil, Switzerland.
Anatol LutherBachem AG, Hauptstrasse 114, 4416 Bubendorf, Switzerland.
Daniel ObrechtPolyphor Ltd, Hegenheimermattweg 125, 4123 Allschwil, Switzerland.
Philipp ErmertPolyphor Ltd, Hegenheimermattweg 125, 4123 Allschwil, Switzerland.
Polyphor (Switzerland) · CHBachem (Switzerland) · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This review covers some of the recent progress in the field of peptide antibiotics with a focus on compounds with novel or established mode of action and with demonstrated efficacy in animal infection models. Novel drug discovery approaches, linear and macrocyclic peptide antibiotics, lipopeptides like the polymyxins as well as peptides addressing targets located in the plasma membrane or in the outer membrane of bacterial cells are discussed.

Indexed as

ADMET, absorption, distribution, metabolism and excretion – toxicity in pharmacokineticsAMP, antimicrobial peptideAMR, antimicrobial resistanceAntibioticantimicrobial peptideantimicrobial resistanceATCC, ATCC cell collectionBAM, β-barrel assembly machinerybid, bis in die (two times a day)CC50, cytotoxic concentration to kill 50% of cellsCD, circular dichroismCFU, colony forming unitCLSI, clinical and laboratory standards instituteCMS, colistin methane sulfonateDMPC, 1,2-dimyristoyl-sn-glycero-3-phosphocholineESKAPE, acronym encompassing six bacterial pathogens (often carrying antibiotic resistance): Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter sppFDA, U. S. Food and Drug AdministrationHABP, hospital acquired bacterial pneumoniaHDP, host-defense peptideHEK293, human embryonic kidney 293 cellsHepG2, human hepatocellular carcinoma cell lineHK-2, human kidney 2 cells (proximal tubular cell line)Hpg, 4-hydroxy-phenyl glycinei.p., intraperitonealITC, isothermal titration calorimetryi.v., intravenousKPC, Klebsiella pneumoniae metallo-β-lactamase C resistantlipopeptideLPS, lipopolysaccharideLptA, lipopolysaccharide transport protein ALptC, lipopolysaccharide transport protein CLptD, lipopolysaccharide transport protein DMDR, multidrug-resistantMH-II, Müller-Hinton broth II (cation adjusted)MH-I, Müller-Hinton broth IMIC, minimal inhibitory concentrationmITT population, minimal intend-to-treat populationMoA, mechanism (mode) of actionMRSA, methicilline-resistant S. aureusMSSA, methicilline-sensitive S. aureusNDM-1, New Delhi metallo-β-lactamase resistantNOAEL, no adverse effect levelODL, odilorhabdinOmp, outer membrane proteinOMPTA (outer membrane targeting antibiotic)OMPTA, outer membrane targeting antibioticPBMC, peripheral mononuclear blood cellPBP, penicillin-binding proteinPBS, phosphate-buffered salinepeptide antibioticPK, pharmacokineticsPOPC, 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholinePOPG, 2-oleoyl-1-palmitoyl-sn-glycero-3-phospho-(1-glycerol)PrAMPs, polyproline antimicrobial peptidesRBC, red blood cellSAR, structure-activity relationships.c., subcutaneousSPase I, signal peptidase ISPR, surface plasmon resonanceVABP, ventilator associated bacterial pneumoniaVIM-1, beta-lactamase 2 (K. pneumoniae)VISA, vancomycin-intermediate S. aureusVRE, vancomycin-resistant enterococcusWHO, World Health OrganizationWTA, wall teichoic acidWT, wild typeXDR, extremely drug-resistant

Identifiers

PMID33398258
PMCPMC7773004
OpenAlexW3115709214

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.